<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63842">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02009137</url>
  </required_header>
  <id_info>
    <org_study_id>E1307-210-002</org_study_id>
    <secondary_id>06-2013-175-GNSD</secondary_id>
    <nct_id>NCT02009137</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of EVERA to Augment Small Breast</brief_title>
  <official_title>Breast Augmentation Using EVERA - Comparative Clinical Trial With ESTES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Ministry of Education, Science, and Technology</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Expected Total Number of Subjects

        -  Level of significance, alfa 0.05

        -  Power 0.80

        -  Mean difference between two treatments is assumed 35

        -  Standard Deviation is assumed 35.

        -  Follow-up loss is assumed 20%

        -  N=34(each group:17)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design

        -  single center, randomized, unblind clinical study Medical device

        -  Investigational Medical Device: EVERA

        -  Comparator:  ESTES Process

        -  For eligible subjects, investigator apply Standard Deviation or Comparator on the
           breast

        -  The  Investigational Medical Device  is determined by randomization.

        -  Subjects will be applied  for 12 weeks.

        -  Subjects will receive Patient Compliance Diary

        -  Subjects will visit the hospital to measure breast volume with VIVID 9i every 2 weeks
           for 16weeks
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The change in breast volume of the test group and control group</measure>
    <time_frame>Baseline and 12weeks and 16weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in satisfaction level on their breast</measure>
    <time_frame>Baseline and 12weeks and 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Atrophy of Breast</condition>
  <arm_group>
    <arm_group_label>EVERA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EVERA- korean ESTES system, apply for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESTES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ESTES apply for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EVERA</intervention_name>
    <description>EVERA apply for 12 weeks</description>
    <arm_group_label>EVERA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ESTES</intervention_name>
    <description>ESTES apply for 12 weeks</description>
    <arm_group_label>ESTES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female aged between 24 and 40

          -  BMI of over 20

          -  Subjects who want to augment breasts

          -  Subjects who understand the study contents and signed the informed consent

          -  Subjects who can follow study procedure

        Exclusion Criteria:

          -  Pregnant or Lactating subjects
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chanyeong - Heo, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National Univ. Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gumi-dong, Bundang-gu/Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 1, 2014</lastchanged_date>
  <firstreceived_date>December 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Chan-Yeong Heo</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>small breast</keyword>
  <keyword>augmentation</keyword>
  <keyword>breast volume</keyword>
  <keyword>External Soft Tissue Expansion System(ESTES)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
